JP2017515892A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515892A5
JP2017515892A5 JP2017507675A JP2017507675A JP2017515892A5 JP 2017515892 A5 JP2017515892 A5 JP 2017515892A5 JP 2017507675 A JP2017507675 A JP 2017507675A JP 2017507675 A JP2017507675 A JP 2017507675A JP 2017515892 A5 JP2017515892 A5 JP 2017515892A5
Authority
JP
Japan
Prior art keywords
solution according
component
solution
hydrogen carbonate
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017507675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515892A (ja
JP6488003B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/017994 external-priority patent/WO2015163978A1/en
Publication of JP2017515892A publication Critical patent/JP2017515892A/ja
Publication of JP2017515892A5 publication Critical patent/JP2017515892A5/ja
Application granted granted Critical
Publication of JP6488003B2 publication Critical patent/JP6488003B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017507675A 2014-04-25 2015-02-27 安定なモンテルカスト溶液 Expired - Fee Related JP6488003B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461984098P 2014-04-25 2014-04-25
US61/984,098 2014-04-25
PCT/US2015/017994 WO2015163978A1 (en) 2014-04-25 2015-02-27 A stable montelukast solution

Publications (3)

Publication Number Publication Date
JP2017515892A JP2017515892A (ja) 2017-06-15
JP2017515892A5 true JP2017515892A5 (enExample) 2018-04-05
JP6488003B2 JP6488003B2 (ja) 2019-03-20

Family

ID=54332972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507675A Expired - Fee Related JP6488003B2 (ja) 2014-04-25 2015-02-27 安定なモンテルカスト溶液

Country Status (5)

Country Link
US (1) US9717684B2 (enExample)
EP (1) EP3134076A4 (enExample)
JP (1) JP6488003B2 (enExample)
CN (1) CN106456535B (enExample)
WO (1) WO2015163978A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017038732A1 (ja) * 2015-08-31 2017-03-09 大蔵製薬株式会社 モンテルカストの含水医薬製剤
CN108201525A (zh) * 2017-12-14 2018-06-26 重庆西南医院 一种促进孟鲁司特钠经鼻吸收促进剂及其使用方法
JP7049610B2 (ja) * 2018-05-21 2022-04-07 高田製薬株式会社 レボセチリジン固形製剤
CN108888602B (zh) * 2018-08-16 2021-04-06 海南锦瑞制药有限公司 一种孟鲁司特钠制剂及其制备方法
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
WO2022103634A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of epilepsy
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1678139B1 (en) 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
BRPI0506610A (pt) 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
WO2005089761A1 (en) 2004-03-17 2005-09-29 Pfizer Limited Combination for treating inflammatory diseases
TWI314454B (en) * 2005-01-04 2009-09-11 Ct Lab Inc An oral liquid pharmaceutical composition of leukotriene antagonists
WO2007005965A1 (en) * 2005-07-05 2007-01-11 Teva Paharmaceutical Industries Ltd. Purification of montelukast
CA2616129A1 (en) * 2005-07-20 2007-01-25 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
US20090182148A1 (en) 2005-12-23 2009-07-16 Harmander Singh Pal Chawla Process for the manufacture of montelukast sodium
RS51330B (sr) * 2006-02-09 2011-02-28 Teva Pharmaceutical Industries Ltd. Stabilne farmaceutske formulacije montelukast natrijuma
IL181607A0 (en) 2006-02-27 2007-07-04 Chemagis Ltd Novel process for preparing montelukast and salts thereof
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
SI22382A (sl) 2006-10-26 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek za pripravo montelukasta
EP2094665A4 (en) 2006-11-06 2010-11-24 Reddys Lab Ltd Dr PREPARATION OF MONTELUKAST AND ITS SALTS
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
WO2012066401A1 (en) 2010-11-16 2012-05-24 Lupin Limited Stable oral pharmaceutical compositions of montelukast
CN103781467B (zh) 2011-09-16 2016-08-31 辉凌公司 一种快速溶解药物组合物
KR20130076015A (ko) 2011-12-28 2013-07-08 주식회사 삼양바이오팜 높은 경도를 갖는 속붕정 및 이의 제조 방법
KR101418404B1 (ko) 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
CN103239450B (zh) * 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法

Similar Documents

Publication Publication Date Title
JP2017515892A5 (enExample)
IN2014DN09973A (enExample)
JP2014515039A5 (enExample)
JP2016540701A5 (enExample)
WO2013085810A3 (en) Co-attrited stabilizer composition
UA96342C2 (en) Microspheres having core/shell structure
JP2016539873A5 (enExample)
JP2018184433A5 (enExample)
NO20084292L (no) Formulering for legemiddellevering til kolon
NO20091988L (no) Naturlig ekvivalent av kjemisk modifisert stivelse
CA3055355C (en) RADIO LINK FAILURE MANAGEMENT METHOD AND ASSOCIATED PRODUCT
WO2013057168A3 (en) Granules comprising an active substance
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
BR112012003609A2 (pt) proteína que possui atividade de beta-glucosidase e usos da mesma
CN106459885A (zh) 表达阿维菌素类似物的重组微生物及其用途
WO2015051885A3 (de) Verfahren zum herstellen von halobutyl-kautschuk
JP2015147762A5 (enExample)
Samy et al. DAMPs and influenza virus infection in ageing
EP4102986A4 (en) EXPANDED DRY PRODUCT FOR CALORIC RESTRICTION AND FOR SATIATION EFFECT, USES AND METHODS FOR THE PRODUCTION THEREOF
WO2014173941A3 (fr) Procédé d'obtention d'un gel stable d'acide hyaluronique et d'une forme libre de vitamine c et/ou de l'un de ses sels
WO2019122749A8 (fr) Procédé de préparation d'un amidon thermiquement modifié
CN102924609A (zh) 一种分步法生产低取代羟丙基纤维素的方法
MX2017015835A (es) Gel oftalmico de bimatoprost aplicable en gotas.
WO2008042499A3 (en) Process for making jelly containing pectin
EA201991965A1 (ru) Повторное увлажнение крахмала и/или муки, подвергнутых сшиванию посредством термообработки